Study: Single daily ribavirin dose doesn't increase adverse effects

03/27/2013 | Medscape (free registration)

Researchers at the Icahn School of Medicine at Mount Sinai in New York found once-daily ribavirin treatment did not increase the risk of adverse gastrointestinal events in hepatitis C patients being treated with triple therapy. The results were presented at the International Conference on Viral Hepatitis.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX